Regulatory interacting network between the immunomodulatory non-coding RNAs: miR-17-5p, MALAT1 and H19 lncRNAs in modulating the tumour microenvironment in TNBC

Soliman, R.A.; Youness, R.A.; El‐Shazly, Mohamed; Handoussa, Heba; Gad, Monika

doi:10.1093/annonc/mdz452.032

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was supported by evidence that was reported by Li et al that MALAT-1 could directly sponge miR-34a in melanoma cells [54] and directly target miR-17–5p in macrophages [55] . Nonetheless, our group and others have recently proven the tumor suppressor effects of both miRNAs in TNBC cells [ 28 , 56 ] and their possible immunomodulatory role in several malignancies [ 57 , 58 ]. To confirm our hypothesis, expression profiling of the selected miRNAs was performed in the same cohort of BC patients recruited in the current study.…”

Section: Discussionmentioning

confidence: 99%

“…Such strategies represent a vicious evasion mechanism that obverts immune responses against tumors [15] . Another tactic that has been extensively studied by our research group is hijacking the immune-surveillance by TNBC tumors via genetic and epigenetic alterations which modulate several components of TME, consequently suppressing the infiltrating immune cellular activity [16] , [17] , [18] , [19] , [20] , [21] , [22] . Accordingly, re-sensitizing the cytotoxic immune cells at the TME through reversing these immunoediting processes is considered a milestone towards the development of more effective immunotherapeutic therapeutic modality.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer

Mekky

Ragab²,

Manie

et al. 2023

Translational Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer

Mekky

Ragab²,

Manie

et al. 2023

Translational Oncology

View full text Add to dashboard Cite

“…Prostate cancer-associated 3 (PCA3) has, in particular, been approved by the FDA and is currently being sold as Progensa by Hologic Gen-Probe (Marlborough, MA, USA) for prostate cancer diagnosis [185]. Circulating ncRNAs such as PCA3 are more reliable than other CNAs due to their high stability in the bloodstream and resistance to nuclease-mediated fragmentation, as extensively studied and reviewed by our research group in [186][187][188][189][190][191]. Plasma lncRNAs, in particular, were reported to be less sensitive to degradation induced via repetitive freeze-thaw cycles, as well as prolonged exposure to 45 • C and room temperature [192].…”

Section: Hcc Immunotherapymentioning

confidence: 99%

Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy

Abaza,

El-Aziz,

Daniel

et al. 2023

IJMS

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a highly fatal malignancy with limited therapeutic options and high recurrence rates. Recently, immunotherapeutic agents such as immune checkpoint inhibitors (ICIs) have emerged as a new paradigm shift in oncology. ICIs, such as programmed cell death protein 1 (PD-1) inhibitors, have provided a new source of hope for patients with advanced HCC. Yet, the eligibility criteria of HCC patients for ICIs are still a missing piece in the puzzle. Circular RNAs (circRNAs) have recently emerged as a new class of non-coding RNAs that play a fundamental role in cancer pathogenesis. Structurally, circRNAs are resistant to exonucleolytic degradation and have a longer half-life than their linear counterparts. Functionally, circRNAs possess the capability to influence various facets of the tumor microenvironment, especially at the HCC tumor–immune synapse. Notably, circRNAs have been observed to control the expression of immune checkpoint molecules within tumor cells, potentially impeding the therapeutic effectiveness of ICIs. Therefore, this renders them potential cancer-immune biomarkers for diagnosis, prognosis, and therapeutic regimen determinants. In this review, the authors shed light on the structure and functional roles of circRNAs and, most importantly, highlight the promising roles of circRNAs in HCC immunomodulation and their potential as promising biomarkers and immunotherapeutic regimen determinants.

show abstract

“…Their interactions with microRNAs, mRNAs, proteins, and genomic DNA control their physiological and pathological roles. Transcribing long noncoding RNAs (LncRNAs) from loci connected to cancer has been proposed as a major contributor to cancer risk, since deregulation of gene expression is a key event in carcinogenesis [9].…”

Section: Introductionmentioning

confidence: 99%

Investigating diagnostic, Prognostic, and therapeutic role of Long Non-Coding RNA MALAT1 in Breast Carcinoma:<i> in silico</i> study

Shuja,

Shahbaz,

Sharif

et al. 2024

Dev. med. life sci.

View full text Add to dashboard Cite

Background: Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) is a nuclear-enriched long non-coding RNA, implicated in the tumorigenesis of various cancers, including breast carcinoma (BC). It is associated with cancer proliferation, invasion, migration, and metastasis, and plays a role in immune system modulation. Aims and Objectives: This in silico study investigates MALAT1's diagnostic, prognostic, and therapeutic potential in BC. It examines MALAT1's differential expression in Breast Cancer (BC) versus normal tissues, its impact on patient survival, and its interaction with miR-561 affecting TOP2A mRNA degradation. Methodology: Using publicly available datasets from GEO and TCGA, we conducted differential expression, survival, and prognostic analyses, along with network and pathway studies and drug repurposing analyzes and Tools like Graph Pad Prism and GEPIA data set was used for demographics. Results: Our analyzes indicate overexpression of MALAT1 in BC tissues, its correlation with poorer survival rates, and involvement in key oncogenic pathways. Additionally, drug repurposing analyzes have identified potential MALAT1-targeted therapeutic strategies. Conclusion: MALAT1 serves as a significant biomarker for BC diagnosis and prognosis and is identified as a potential therapeutic target. This study lays the groundwork for future research into MALAT1-targeted therapies in BC

show abstract

Regulatory interacting network between the immunomodulatory non-coding RNAs: miR-17-5p, MALAT1 and H19 lncRNAs in modulating the tumour microenvironment in TNBC

Cited by 5 publications

References 0 publications

MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer

MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer

Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy

Investigating diagnostic, Prognostic, and therapeutic role of Long Non-Coding RNA MALAT1 in Breast Carcinoma:<i> in silico</i> study

Contact Info

Product

Resources

About